Then figure out the intentions of IDG and Goldman Sachs.
Currently, SecondMind's shareholders are only Goldman Sachs, IDG, Tencent, Cambridge University Investment Fund, and the founder.
The shareholding structure is simple, but there are no easy characters among them.
......
Kechuang Bio released an announcement at midnight on New Year's Day. The gist of the announcement was:
"Science and Technology Innovation Biotechnology has completed the research and development of brain-computer interface mobile phones for all races in English. Patents are being registered globally, and patent licensing negotiations have been launched simultaneously with major mobile phone manufacturers."
It also explained that the licensing price for English-language brain-computer interface patents needs to be adjusted, and will not be as low as the licensing price of Chinese-language patents, which is 200 RMB per mobile phone.
As soon as the news broke, the top ten science and technology innovation biotech stock forums were quickly pushed to the top spot:
"The good news has been priced in; a sharp drop from the high point is imminent!"
Such comments are not uncommon. Not only is there some truth to the sharp drop from high levels, but people on stock forums also tend to have a mentality that if a company releases positive news but they don't hold any shares, they will blindly be bearish.
"The current price of Kechuang Bio is only over 2,000 yuan, which is not high. It is expected to reach 3,000 yuan in the short term."
Currently, Sci-Tech Biotechnology and Kweichow Moutai are the only two companies in the A-share market with a stock price exceeding 2,000 yuan.
Liquor stocks have been rising continuously, to the point that investors jokingly refer to China's technology stocks as "sauce-flavored technology" and "strong-flavored technology."
Most investors would prefer to see technology stocks representing China's stock market rather than liquor companies.
"The patent licensing for English-language brain-computer interface with mobile phones will generate at least 6 billion RMB in profit for Kechuang Bio in 2022, based on the current patent licensing price."
If the price is renegotiated, net profit will increase further.
Profit is not the most important thing. What is more crucial is that Kechuang Bio was the first to issue an announcement, indicating that it remains the strongest company in the field of brain-computer interfaces.
Kechuang Bio's revenue in the field of brain-computer interfaces is more than the combined revenue of all other companies in the field.
Why wouldn't you build a position in a company with such core, monopolistic technology that maintains high growth and profits?
Continue read on readnovelmtl.com
